The European orthopedic biomaterials market is expected to reach ?376.7 million by 2019, with hyaluronic acid viscosupplementation as the largest segment.The European orthopedic biomaterials market includes bone graft substitutes (BGS), hyaluronic acid (HA) viscosupplementation, bone morphogenetic protein (BMP) growth factor therapy and autologous chondrocyte implantation (ACI). As the market continued to recover from the economic crisis, slow growth was often seen across different regions. The ACI market underwent drastic changes in 2012 due to modifications in the European Medicines Agency (EMA) regulations.While autografts were still commonly used in 2012, easy accessibility and p...
No comments:
Post a Comment